Overview of Referral of CAR T for Early R/R Multiple Myeloma

Aimee Merino, MD, discusses how the referral process for chimeric antigen receptor T-cell therapy in early relapsed/refractory multiple myeloma involves assessing eligibility, identifying potential roadblocks, and determining which patients may not be suitable for referral based on clinical factors and treatment goals.

EP: 1.A 60-Year-Old Man With Early Relapse Multiple Myeloma

EP: 2.Identification, Evaluation, and Management of High-Risk Disease in Early R/R MM

Now Viewing

EP: 3.Overview of Referral of CAR T for Early R/R Multiple Myeloma

EP: 4.CARTITUDE-4: Latest Data of Cilta-Cel for Early R/R MM

Video content above is prompted by the following:

• What is the referral process for patients being considered for chimeric antigen receptor (CAR) T-cell therapy in early relapsed/refractory multiple myeloma?
• What are the potential roadblocks to CAR T referral?
• Which patients would you not refer for CAR T therapy in this setting?

Recent Videos